BioSpace News Archive

Immunyx Pharma announced it has been selected to join Blue Knight , a collaboration between Johnson & Johnson Innovation LLC and the Biomedical Advanced Research and Development Authority (‘BARDA’) within the Administration for Strategic Preparedness and Response (ASPR), a part of the U.S. Department of Health and Human Services, (HHS).

Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for NGN-401 for the treatment of Rett syndrome.

Cadrenal Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib).

Biotricity Inc. announced today that Company CEO Waqaas Alsiddiq has been invited to present at the Healthcare IT Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, January 25th, 2023 at 8:15 a.m. ET.

NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced new in vitro study results demonstrating the agonist effect of mazindol ER at the Orexin-2 Receptor (OX2R).

A novel method for supporting and recovering donor lungs outside the body shows potential to increase the number of organs available for transplant, according to a recent study published in The Journal of Heart and Lung Transplantation.

BIOASIS TECHNOLOGIES INC today announced that it has terminated the arrangement agreement (the “Arrangement Agreement”) dated December 13, 2022, as amended December 18, 2022, between Bioasis and Midatech Pharma plc (“Midatech”).

Inspira™ Technologies announced today that the novel convertible dual lumen cannula device and method of use, being developed for the INSPIRA™ ART System, has been granted a patent by the U.S. Patent and Trademark Office (USPTO).

Benitec Biopharma Inc. today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program.

BioCareSD, a specialty distributor of life-saving therapies, is proud to announce the addition of LEQEMBI to their diverse portfolio of specialty therapeutics.